Pneumocystis Pneumonia during Rituximab Treatment in Children with Autoimmune Nerve System Diseases
- 14 Downloads
We thank Prof. Russell C. Dale of the Children’s Hospital at Westmead, University of Sydney for the great ideas in this study and the revision for this paper.
Compliance with Ethical Standards
The study was approved by the Ethics Committee of the Peking University First Hospital.
Patients were gave written informed consent.
Conflict of Interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M (2014) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83:142–150CrossRefPubMedPubMedCentralGoogle Scholar
- Jiang X, Mei X, Feng D, Wang X (2015) Prophylaxis and treatment of pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One 10:e122171Google Scholar